

***AESKULISA* Glia-A**

Protocol 30-30-30 REF30-7501US



# Instruction manual

## Contents

---

|                                                          |     |
|----------------------------------------------------------|-----|
| 1. Intended Use.....                                     | 2   |
| 2. Clinical Applications and Principle of the Assay..... | 2   |
| 3. Kit Contents.....                                     | 3   |
| 4. Storage and Shelf Life.....                           | 3   |
| 5. Precautions of Use.....                               | 4   |
| 6. Sample Collection, Handling and Storage.....          | 4   |
| 7. Assay Procedure.....                                  | 5   |
| 8. Semi-Quantitative and Qualitative Interpretation..... | 6   |
| 9. Technical Data.....                                   | 7   |
| 10. Performance Data.....                                | 7-9 |
| 11. Literature.....                                      | 9   |
| A : Pipetting scheme.....                                | 10  |
| B : Test Procedure.....                                  | 11  |

## 1. Intended Use

---

The **AESKULISA GLIA-A** is a solid phase enzyme immunoassay for the semi-quantitative and qualitative detection of IgA antibodies against gliadin in human serum.

The assay is an aid in the diagnosis of celiac disease (gluten-sensitive enteropathy) and should be used in conjunction with other serological tests and clinical findings.

## 2. Clinical Application and Principle of the Assay

---

Gluten-sensitive enteropathy or celiac disease is characterized by atrophy of the small intestinal villi leading to a so-called flat mucosa. It is caused by a pathological intolerance to Gliadin, the alcohol-soluble fraction of gluten in wheat, rye and barley. The disease is HLA-associated (>95% of patients have DQ2 enREFd by DQA1\*0501 and DQB1\*0201) and manifests at any age with a peak onset in early childhood, even in neonatals. The incidence rates range from 1 in 4000 to 1 in 300 in european countries.<sup>1-4</sup>

Diagnosis of celiac disease is made by small intestinal biopsy (demonstrating the flat mucosa) supported by serological markers. Antibodies against Gliadin and tissue Transglutaminase (tTG) are of major significance. tTG has been identified as the major target antigen of EMA, antibodies binding to endomysium (extracellular constituent of smooth muscle) in indirect immunofluorescence test (IFT), which has been so far an important tool for the diagnosis of celiac diseases.<sup>2,5</sup>

Circulating IgG and IgA antibodies to Gliadin are found in the serum of most but not all celiac disease patients, though the specificity of these antibodies are significantly lower compared to tTG and EMA. The determination of IgG antibodies to Gliadin (and/or tTG) is especially of high value as approximately 2% - 5% of celiac patients display an IgA deficiency, thus being missed by IgA subclass tests.<sup>5</sup>

Antibodies to Gliadin may be the only serological marker in neonatals, as anti-tTG and EMA autoantibodies are not present at this age. Consequently anti-Gliadin antibodies are the earliest serological marker for pediatricians when diagnosing celiac disease.<sup>1,4,6,7</sup>

### ***Principle of the test***

Serum samples diluted 1:101 are incubated in the microplates coated with the specific antigen. Patient's antibodies, if present in the specimen, bind to the antigen. The unbound fraction is washed off in the following step. Afterwards anti-human immunoglobulins conjugated to horseradish peroxidase (conjugate) are incubated and react with the antigen-antibody complex of the samples in the microplates. Unbound conjugate is washed off in the following step. Addition of TMB-substrate generates an enzymatic colorimetric (blue) reaction, which is stopped by diluted acid (color changes to yellow). The rate of color formation from the chromogen is a function of the amount of conjugate bound to the antigen-antibody complex and this is proportional to the initial concentration of the respective antibodies in the patient sample.

### 3. Kit Contents

---

#### **To be reconstituted:**

5x Sample Buffer 1 vial, 20 ml - 5x concentrated (capped white: yellow solution)

Containing: Tris, NaCl, BSA, sodium azide < 0.1%

50x Wash Buffer 1 vial, 20 ml - 50x concentrated (capped white: green solution)

Containing: Tris, NaCl, Tween-20, sodium azide < 0.1%

#### **Ready to use:**

Negative Control 1 vial, 1.5 ml (capped green: yellow solution)

Containing: PBS, BSA, Human serum (diluted), sodium azide < 0,1% (preservative)

Positive Control 1 vial, 1.5 ml (capped red: yellow solution)

Containing: PBS, BSA, Human serum (diluted), sodium azide < 0,1% (preservative)

Cut-off Control 1 vial, 1.5 ml (capped blue: yellow solution)

Containing: PBS, BSA, Human serum (diluted), sodium azide < 0,1% (preservative)

Calibrators 6 vials, 1.5 ml each 0, 3, 10, 30, 100, 300 U/ml

(color increasing with concentration: yellow solutions)

Containing: PBS, BSA, Human serum (diluted), sodium azide < 0,1% (preservative)

Conjugate 1 vial, 15 ml IgA (capped red: red solution)

Containing: PBS, BSA, Anti-human immunoglobulins conjugated to horseradish peroxidase

TMB Substrate 1 vial, 15 ml (capped black)

Containing: Stabilized TMB/H<sub>2</sub>O<sub>2</sub>

Stop Solution 1 vial, 15 ml (capped white: colorless solution)

Containing: 1M Hydrochloric Acid

Microtiterplate 12x8 well strips with breakaway microwells

Coated with purified alpha-Gliadin

#### **Material required but not provided:**

Microtiter plate reader 450 nm reading filter and optional 620 nm reference filter (600-690 nm). Glass ware (cylinder 100-1000ml), test tubes for dilutions. Vortex mixer, precision pipettes (10, 100, 200, 500, 1000 µl) or adjustable multipipette (100-1000µl). Microplate washing device (300 µl repeating or multi-channel pipette or automated system), adsorbent paper.

Our tests are designed to be used with purified water according to the definition of the United States Pharmacopeia (USP 26 - NF 21) and the European Pharmacopeia (Eur.Ph. 4th ed.).

### 4. Storage and Shelf Life

---

Store all reagents and the microplate at 2-8°C/35-46°F, in their original containers. Once prepared, reconstituted solutions are stable for 1 month at 4°C/39°F, at least. **Reagents and the microplate shall be used within the expiry date indicated on each component, only. Avoid intense exposure of TMB solution to light. Store microplates in designated foil, including the desiccant, and seal tightly.**

## 5. Precautions of Use

---

### 5.1 Health hazard data

**THIS PRODUCT IS FOR IN VITRO DIAGNOSTIC USE ONLY.** Thus, only staff trained and specially advised in methods of in vitro diagnostics may perform the kit. Although this product is not considered particularly toxic or dangerous in conditions of normal use, refer to the following for maximum safety :

#### **Recommendations and precautions**

This kit contains potentially hazardous components. Though kit reagents are not classified being irritant to eyes and skin we recommend to avoid contact with eyes and skin and wear disposable gloves. **WARNING!** Calibrators, Controls and Buffers contain sodium azide ( $\text{NaN}_3$ ) as a preservative .  $\text{NaN}_3$  may be toxic if ingested or adsorbed by skin or eyes.  $\text{NaN}_3$  may react with lead and copper plumbing to form highly explosive metal azides. On disposal, flush with a large volume of water to prevent azide build-up. Please refer to decontamination procedures as outlined by CDC or other local/national guidelines.

Do not smoke, eat or drink when manipulating the kit.

Do not pipette by mouth.

All human source material used for some reagents of this kit (controls, standards e.g.) has been tested by FDA approved methods and found negative for HbsAg, Hepatitis C and HIV 1. However, no test can guarantee the absence of viral agents in such material completely. Thus handle kit controls, standards and patient samples as if capable of transmitting infectious diseases and according to national requirements.

### 5.2 General directions for use

Do not mix or substitute reagents or microplates from different lot numbers. This may lead to variations in the results.

Allow all components to reach room temperature (20-26°C/64-78.8°F) before use, mix well and follow the recommended incubation scheme for an optimum performance of the test.

Never expose components to higher temperature than 37°C/ 98,6 °F.

Always pipette substrate solution with brand new tips only. Protect this reagent from light. Never pipette conjugate with tips used with other reagents prior.

### Limitations

**A definite clinical diagnosis should not be based on the results of the performed test only, but should be made by the physician after all clinical and laboratory findings have been evaluated. The diagnosis is to be verified using different diagnostic methods.**

**The performance of the assay has not been established with pediatric samples.**

**In some cases gliadin antibodies may also be present in other autoimmune diseases or celiac patients following a gluten-free diet (see comparative data Section 10.2).**

## 6. Sample Collection, Handling and Storage

---

Use preferentially freshly collected serum samples. Blood withdrawal must follow national requirements. Do not use icteric, lipemic, hemolysed or bacterially contaminated samples. Sera with particles should be cleared by low speed centrifugation (<1000 x g). Blood samples should be collected in clean, dry and empty tubes. After separation, the serum samples should be used immediately, respectively stored tightly closed at 2-8°C/35-46°F up to three days, or frozen at -20°C/-4°F for longer periods.

## 7. Assay Procedure

---

### 7.1 Preparations prior to pipetting

Dilute concentrated reagents:

Dilute the concentrated sample buffer 1:5 with distilled water (e.g. 20 ml plus 80 ml).

Dilute the concentrated wash buffer 1:50 with distilled water (e.g. 20 ml plus 980 ml).

### Samples

Dilute serum samples 1:101 with sample buffer (1x)

e.g. 1000 µl sample buffer (1x) + 10 µl serum. Mix well !

### Washing

Prepare 20 ml of diluted wash buffer (1x) per 8 wells or 200 ml for 96 wells

(e.g. 4 ml concentrate plus 196 ml distilled water).

### Automated washing:

Consider excess volumes required for setting up the instrument and dead volume of robot pipette.

### Manual washing:

Discard liquid from wells by inverting the plate. Knock the microwell frame with wells downside vigorously on clean adsorbent paper. Pipette 300 µl of diluted wash buffer into each well, wait for 20 seconds. Repeat the whole procedure twice again.

### Microplates

Calculate the number of wells required for the test. Remove unused wells from the frame, replace and store in the provided plastic bag, together with desiccant, seal tightly (2-8°C/35-46°F).

### 7.2 Work flow

**For pipetting scheme see Annex A, for the test procedure see Annex B  
We recommend pipetting samples and calibrators in duplicate.**

- Pipette 100 µl of each patient's diluted serum into the designated microwells.
- Pipette 100 µl calibrators OR cut-off control and negative and positive controls into the designated wells.
- Incubate for 30 minutes at room temperature (20-26°C/64-78.8°F).
- Wash 3x with 300 µl washing buffer (diluted 1:50).
- Pipette 100 µl conjugate into each well.
- Incubate for 30 minutes at room temperature (20-26°C/64-78.8°F).
- Wash 3x with 300 µl washing buffer (diluted 1:50).
- Pipette 100 µl TMB substrate into each well.
- Incubate for 30 minutes at room temperature (20-26°C/64-78.8°F).
- Pipette 100 µl stop solution into each well, using the same order as pipetting the substrate.
- Incubate 5 minutes minimum.
- Agitate plate carefully for 5 sec.
- Read absorbance at 450 nm (optionally 450/620 nm) within 30 minutes.

## 8. Semi-Quantitative and Qualitative Interpretation

For **semi-quantitative interpretation** establish the standard curve by plotting the **optical density (OD) of each calibrator (y-axis)** with respect to the corresponding concentration values in **U/ml (x-axis)**. For best results we recommend log/lin coordinates and 4-Parameter Fit. From the OD of each sample, read the corresponding antibody concentrations expressed in **U/ml**.

|                                         |                                                |
|-----------------------------------------|------------------------------------------------|
| <b>Normal Range</b><br><b>≤ 15 U/ml</b> | <b>Positive Results</b><br><b>&gt; 15 U/ml</b> |
|-----------------------------------------|------------------------------------------------|

### Example of a standard curve

We recommend pipetting calibrators in duplicate for each run.

| <b>Calibrators IgA</b> | <b>OD 450/620 nm</b> | <b>CV % (Variation)</b> |
|------------------------|----------------------|-------------------------|
| 0 U/ml                 | 0.059                | 1.4                     |
| 3 U/ml                 | 0.182                | 1.2                     |
| 10 U/ml                | 0.323                | 2.2                     |
| 30 U/ml                | 0.667                | 0.7                     |
| 100 U/ml               | 1.316                | 0.9                     |
| 300 U/ml               | 2.203                | 0.1                     |

### Example of calculation

| <b>Patient</b> | <b>Duplicate (OD)</b> | <b>Mean (OD)</b> | <b>Result (U/ml)</b> |
|----------------|-----------------------|------------------|----------------------|
| P 01           | 0.654/0.633           | 0.644            | 27.6                 |
| P 02           | 1.284/1.263           | 1.274            | 89.9                 |

For lot specific data, see enclosed quality control certificate. Medical laboratories might perform an in-house Quality Control by using own controls and/or internal pooled sera, as foreseen by EU regulations. **Do not use this example for interpreting patients results!**

Each laboratory should establish its own normal range based upon its own techniques, controls, equipment and patient population according to their own established procedures.

For **qualitative interpretation** read the optical density of the cut-off control and the patient samples. Compare patient's OD with the OD of the cut-off control. All samples which are higher than cut-off are considered positive.

|                  |                                             |
|------------------|---------------------------------------------|
| <b>Negative:</b> | <b>OD patient &lt; OD<sub>cut-off</sub></b> |
| <b>Positive:</b> | <b>OD patient &gt; OD<sub>cut-off</sub></b> |



## 9. Technical Data

|                                  |                                                     |
|----------------------------------|-----------------------------------------------------|
| <b>Sample material:</b>          | serum                                               |
| <b>Sample volume:</b>            | 10 µl of sample diluted 1:101 with 1x sample buffer |
| <b>Total incubation time:</b>    | 90 minutes at room temperature (20-26°C/64-78.8°F)  |
| <b>Calibration range:</b>        | 0-300 U/ml                                          |
| <b>Analytical sensitivity:</b>   | 1.0 U/ml                                            |
| <b>Storage:</b>                  | at 2-8°C/35-46°F use original vials, only           |
| <b>Number of determinations:</b> | 96 tests                                            |

## 10. Performance Data

### 10.1 Analytical sensitivity

Testing sample buffer 30 times on AESKULISA Glia A (REF7501US) gave an analytical sensitivity of 1.0 U/ml.

### 10.2 Specificity and sensitivity

The microplates are coated with purified alpha gliadin. 204 sera of patients suffering from Celiac disease, Crohns Disease, Ulcerative Colitis and various other autoimmune diseases have been tested on the AESKULISA Glia A and a predicate device (all tests were performed on the 30-15-15 protocol (REF7501US))

|           |          | diagnosis |          |     |
|-----------|----------|-----------|----------|-----|
|           |          | positive  | negative |     |
| AESKULISA | positive | 17        | 17       | 34  |
| Glia A    | negative | 12        | 132      | 144 |
|           |          | 29        | 149      | 178 |

|               |                  |
|---------------|------------------|
| Agreement*:   | 83.7 % (149/178) |
| Sensitivity*: | 58.6 % (17/29)   |
| Specificity*: | 88.6 % (132/149) |

\* results when IgA deficient celiac patients have been excluded from the calculations.


|           |          | predicate device |          |     |
|-----------|----------|------------------|----------|-----|
|           |          | positive         | negative |     |
| AESKULISA | positive | 14               | 20       | 34  |
| Glia A    | negative | 2                | 168      | 170 |
|           |          | 16               | 188      | 204 |

|                             |                  |
|-----------------------------|------------------|
| Overall percent agreement:  | 89.2 % (182/204) |
| Positive percent agreement: | 87.5 % (14/16)   |
| Negative percent agreement: | 89.4 % (168/188) |

| Disease                           | # Tested | # positive<br>AESKU | # positive<br>pred dev |
|-----------------------------------|----------|---------------------|------------------------|
| Celiac Disease                    | 29       | 17                  | 7                      |
| Celiac Disease (gluten free diet) | 42       | 5                   | 0                      |
| Celiac Disease (IgA deficient)    | 26       | 0                   | 0                      |
| Crohns Disease                    | 25       | 5                   | 4                      |
| Ulcerative Colitis                | 6        | 2                   | 2                      |
| Helminthiasis                     | 1        | 0                   | 0                      |
| Lactose Intolerance               | 1        | 1                   | 1                      |
| Mixed connective tissue disease   | 1        | 0                   | 0                      |
| Arthritis (chron/reactive)        | 33       | 2                   | 1                      |
| Wegeners Granulomatosis           | 2        | 0                   | 0                      |
| SLE                               | 29       | 2                   | 1                      |
| healthy donors                    | 9        | 0                   | 0                      |

The data has been acquired with the AESKULISA Gliadin A (REF7501US). The comparability of these data was assessed with 58 sera tested on both, REF 7501US (30-15-15 minute protocol) and REF 30-7501US (30-30-30 protocol). A linear regression analysis of the two products showed that the two protocols are equivalent. Included in these sera are 42 sera close to the cut-off (Range 10-20 U/ml is the upper left panel)

| $Y = b[0] + b[1]X$ | value | range (CI95%) |
|--------------------|-------|---------------|
| $b[0]$             | 0.013 | -0.85 / 0.88  |
| $b[1]$             | 0.94  | 0.907 / 0.975 |
| $r^2$              | 0.99  |               |



### 10.3 Linearity

Chosen sera have been tested with this kit and found to dilute linearly. However, due to the heterogeneous nature of human autoantibodies there might be samples that do not follow this rule. (all tests were performed on the 30-15-15 protocol (REF7501US))

| Sample No. | Dilution Factor | measured concentration (U/ml) | expected concentration (U/ml) | Recovery (%)<br>90 - 110 % |
|------------|-----------------|-------------------------------|-------------------------------|----------------------------|
| 1          | 1 / 100         | 102.5                         | 100.9                         | 101.6                      |
|            | 1 / 200         | 52.4                          | 50.5                          | 103.8                      |
|            | 1 / 400         | 26.3                          | 25.2                          | 104.4                      |
|            | 1 / 800         | 13.0                          | 12.6                          | 103.2                      |
| 2          | 1 / 100         | 53.7                          | 58.3                          | 92.1                       |
|            | 1 / 200         | 29.8                          | 29.2                          | 102.1                      |
|            | 1 / 400         | 16.0                          | 14.6                          | 109.6                      |
|            | 1 / 800         | 7.4                           | 7.3                           | 101.4                      |

## 10.4 Precision

To determine the precision of the assay, the variability (intra and inter-assay) was assessed by examining its reproducibility on three serum samples selected to represent a range over the standard curve. The data has been acquired with the 30-15-15 protocol (REF 7501US). The accepted range for CV is 10%. (n=24 / 18)

| Intra-Assay |             |        | Inter-Assay |             |        |
|-------------|-------------|--------|-------------|-------------|--------|
| Sample No.  | Mean (U/ml) | CV (%) | Sample No.  | Mean (U/ml) | CV (%) |
| 1           | 13.4        | 4.7    | 1           | 14.6        | 8.8    |
| 2           | 32.2        | 5.9    | 2           | 29.0        | 4.6    |
| 3           | 50.4        | 2.8    | 3           | 46.2        | 3.0    |

## 10.5 Calibration

Due to the lack of international reference calibration this assay is calibrated in arbitrary units (U/ml).

## 11. Literature

---

- Mäki M, Collin P (1997).**  
*Coeliac disease.*  
Lancet 349: 1755-1759.
- Shan L, Molberg O, Parrot I, Hausch F, Filiz F, Gray GM, Sollid LM, Khosla C (2002).**  
*Structural basis for gluten intolerance in Celiac Sprue.*  
Science 297: 2275-2279.
- Logan RFA. (1992)**  
*Problems and pitfalls in epidemiological studies of coeliac disease.*  
Dyn Nutr Res 2: 14–24.
- Green PH, Jabri B. (2003)**  
*Coeliac disease.*  
Lancet 362: 383-391.
- Not T, Horvath K, Hill ID, Partanen J, Hamed A, Magzzú G, Fasano (1998)**  
*Celiac disease in the USA: High prevalence of antiendomysium antibodies in healthy donors.*  
Scand J Gastroenterol. 33: 494-8.
- Schuppan (2000)**  
*Current concepts of celiac disease pathogenesis.*  
Gastroenterol. 119: 234-42.
- Ciccocioppo R, Di Sabatino A, Ara C, Biagi F, Perilli M, Amicosante G, Cifone MG (2003)**  
*Gladin and tissue transglutaminase complexes in normal and coeliac duodenal mucosa.*  
Clin Exp Immunol. 134: 516-24.

## ANNEX A: Pipetting scheme

We suggest pipetting calibrators, controls and samples as follows:

For **semi-quantitative interpretation** use calibrators to establish a standard curve

For **qualitative interpretation** use cut-off control

## ANHANG A: Pipettierschema

Wir empfehlen, die Kalibratoren, Kontrollen und Proben wie folgt zu pipettieren:

Zur **semi-quantitativen Auswertung** verwenden Sie die Kalibratoren zur Erstellung einer Standardkurve.

Zur **qualitativen Auswertung** verwenden Sie die Cut-off Kontrolle.

| For semi-quantitative interpretation use calibrators to establish a standard curve |      |      |    |   |   |
|------------------------------------------------------------------------------------|------|------|----|---|---|
|                                                                                    | 1    | 2    | 3  | 4 | 5 |
| A                                                                                  | CalA | CalE | P1 |   |   |
| B                                                                                  | CalA | CalE | P1 |   |   |
| C                                                                                  | CalB | CalF | P2 |   |   |
| D                                                                                  | CalB | CalF | P2 |   |   |
| E                                                                                  | CalC | PC   | P3 |   |   |
| F                                                                                  | CalC | PC   | P3 |   |   |
| G                                                                                  | CalD | NC   |    |   |   |
| H                                                                                  | CalD | NC   |    |   |   |

| For qualitative interpretation use cut-off control |    |     |   |   |   |
|----------------------------------------------------|----|-----|---|---|---|
|                                                    | 1  | 2   | 3 | 4 | 5 |
| A                                                  | NC | P2  |   |   |   |
| B                                                  | NC | P2  |   |   |   |
| C                                                  | CC | P3  |   |   |   |
| D                                                  | CC | P3  |   |   |   |
| E                                                  | PC | ... |   |   |   |
| F                                                  | PC | ... |   |   |   |
| G                                                  | P1 | ... |   |   |   |
| H                                                  | P1 | ... |   |   |   |

CalA: calibrator A, CalB: calibrator B, CalC: calibrator C, CalD: calibrator D, CalE: calibrator E, CalF: calibrator F

PC: positive control

NC: negative control




CC: Cut-off control

P1: patient 1

P2: patient 2

P3: patient 3

## Annex B: Test Procedure/ Testablauf



Assay/Test: \_\_\_\_\_ Incubation / Inkub. : 1. \_\_\_\_\_ min






















Date/ Datum: \_\_\_\_\_

Temperature/Temperatur: \_\_\_\_\_ °F \_\_\_\_\_ °C 2. \_\_\_\_\_ min

Signature/Unterschrift: \_\_\_\_\_

Name: \_\_\_\_\_ 3. \_\_\_\_\_ min

|   | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
|---|---|---|---|---|---|---|---|---|---|----|----|----|
| A |   |   |   |   |   |   |   |   |   |    |    |    |
| B |   |   |   |   |   |   |   |   |   |    |    |    |
| C |   |   |   |   |   |   |   |   |   |    |    |    |
| D |   |   |   |   |   |   |   |   |   |    |    |    |
| E |   |   |   |   |   |   |   |   |   |    |    |    |
| F |   |   |   |   |   |   |   |   |   |    |    |    |
| G |   |   |   |   |   |   |   |   |   |    |    |    |
| H |   |   |   |   |   |   |   |   |   |    |    |    |

|                                                                                     |                                                                                                                                                                                                                  |                                                                                                                                                                 |
|-------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
|    | <ul style="list-style-type: none"> <li>◆ Diagnosi in vitro</li> <li>◆ Pour diagnostic in vitro</li> <li>◆ In Vitro Diagnostikum</li> <li>◆ Para uso Diagnóstico in vitro</li> </ul>                              | <ul style="list-style-type: none"> <li>◆ For in vitro diagnostic use</li> <li>◆ Para uso diagnóstico in vitro</li> <li>◆ In Vitro Διαγνωστικό μέσο</li> </ul>   |
|    | <ul style="list-style-type: none"> <li>◆ Numero d'ordine</li> <li>◆ Référence Catalogue</li> <li>◆ Bestellnummer</li> <li>◆ Número de catálogo</li> </ul>                                                        | <ul style="list-style-type: none"> <li>◆ Catalogue number</li> <li>◆ Numéro de catálogo</li> <li>◆ Αριθμός παραγγελίας</li> </ul>                               |
|    | <ul style="list-style-type: none"> <li>◆ Descrizione lotto</li> <li>◆ Lot</li> <li>◆ Chargen Bezeichnung</li> <li>◆ Lote</li> </ul>                                                                              | <ul style="list-style-type: none"> <li>◆ Lot</li> <li>◆ Lote</li> <li>◆ Χαρακτηρισμός παρτίδας</li> </ul>                                                       |
|    | <ul style="list-style-type: none"> <li>◆ Conformità europea</li> <li>◆ Déclaration CE de Conformité</li> <li>◆ Europäische Konformität</li> <li>◆ Declaração CE de Conformidade</li> </ul>                       | <ul style="list-style-type: none"> <li>◆ EC Declaration of Conformity</li> <li>◆ Declaración CE de Conformidad</li> <li>◆ Ευρωπαϊκή συμφωνία</li> </ul>         |
|    | <ul style="list-style-type: none"> <li>◆ 96 determinazioni</li> <li>◆ 96 tests</li> <li>◆ 96 Bestimmungen</li> <li>◆ 96 Testes</li> </ul>                                                                        | <ul style="list-style-type: none"> <li>◆ 96 tests</li> <li>◆ 96 pruebas</li> <li>◆ 96 προσδιορισμοί</li> </ul>                                                  |
|    | <ul style="list-style-type: none"> <li>◆ Rispettare le istruzioni per l'uso</li> <li>◆ Voir les instructions d'utilisation</li> <li>◆ Gebrauchsanweisung beachten</li> <li>◆ Ver as instruções de uso</li> </ul> | <ul style="list-style-type: none"> <li>◆ See instructions for use</li> <li>◆ Ver las instrucciones de uso</li> <li>◆ Λάβετε υπόψη τις οδηγίες χρήσης</li> </ul> |
|    | <ul style="list-style-type: none"> <li>◆ Da utilizzarsi entro</li> <li>◆ Utilise avant le</li> <li>◆ Verwendbar bis</li> <li>◆ Utilizar antes de</li> </ul>                                                      | <ul style="list-style-type: none"> <li>◆ Use by</li> <li>◆ Utilizar antes de</li> <li>◆ Χρήση μέχρι</li> </ul>                                                  |
|    | <ul style="list-style-type: none"> <li>◆ Conservare a 2-8°C</li> <li>◆ Conserver à 2-8°C</li> <li>◆ Lagerung bei 2-8°C</li> <li>◆ Conservar entre 2-8°C</li> </ul>                                               | <ul style="list-style-type: none"> <li>◆ Store at 2-8°C (35-46°F)</li> <li>◆ Conservar a 2-8°C</li> <li>◆ Φυλάσσεται στους 2-8°C</li> </ul>                     |
|    | <ul style="list-style-type: none"> <li>◆ Prodotto da</li> <li>◆ Fabriqué par</li> <li>◆ Hergestellt von</li> <li>◆ Fabricado por</li> </ul>                                                                      | <ul style="list-style-type: none"> <li>◆ Manufactured by</li> <li>◆ Fabricado por</li> <li>◆ Κατασκευάζεται από</li> </ul>                                      |
|   | <ul style="list-style-type: none"> <li>◆ Calibratore cut-off</li> <li>◆ Etalon Seuil</li> <li>◆ Grenzwert Kalibrator</li> <li>◆ Calibrador de cut-off</li> </ul>                                                 | <ul style="list-style-type: none"> <li>◆ Cut off Calibrator</li> <li>◆ Calibrador de cut-off</li> <li>◆ Οριακός ορός Αντιδραστήριο βαθμονόμησης</li> </ul>      |
|  | <ul style="list-style-type: none"> <li>◆ Controllo positivo</li> <li>◆ Contrôle Positif</li> <li>◆ Positiv Kontrolle</li> <li>◆ Controllo positivo</li> </ul>                                                    | <ul style="list-style-type: none"> <li>◆ Positive Control</li> <li>◆ Control Positivo</li> <li>◆ Θετικός ορός ελέγχου</li> </ul>                                |
|  | <ul style="list-style-type: none"> <li>◆ Controllo negativo</li> <li>◆ Contrôle Négatif</li> <li>◆ Negativ Kontrolle</li> <li>◆ Controllo negativo</li> </ul>                                                    | <ul style="list-style-type: none"> <li>◆ Negative Control</li> <li>◆ Control Negativo</li> <li>◆ Αρνητικός ορός ελέγχου</li> </ul>                              |
|  | <ul style="list-style-type: none"> <li>◆ Calibratore</li> <li>◆ Etalon</li> <li>◆ Kalibrator</li> <li>◆ Calibrador</li> </ul>                                                                                    | <ul style="list-style-type: none"> <li>◆ Calibrator</li> <li>◆ Calibrador</li> <li>◆ Αντιδραστήριο βαθμονόμησης</li> </ul>                                      |
|  | <ul style="list-style-type: none"> <li>◆ Recupero</li> <li>◆ Corrélation</li> <li>◆ Wiederfindung</li> <li>◆ Recuperação</li> </ul>                                                                              | <ul style="list-style-type: none"> <li>◆ Recovery</li> <li>◆ Recuperado</li> <li>◆ Ανάκτηση</li> </ul>                                                          |
|  | <ul style="list-style-type: none"> <li>◆ Coniugato</li> <li>◆ Conjugé</li> <li>◆ Konjugat</li> <li>◆ Conjugado</li> </ul>                                                                                        | <ul style="list-style-type: none"> <li>◆ Conjugate</li> <li>◆ Conjugado</li> <li>◆ Σύζευγμα</li> </ul>                                                          |
|  | <ul style="list-style-type: none"> <li>◆ Micropiastra rivestita</li> <li>◆ Microplaque sensibilisée</li> <li>◆ Beschichtete Mikrotiterplatte</li> <li>◆ Microplaca revestida</li> </ul>                          | <ul style="list-style-type: none"> <li>◆ Coated microtiter plate</li> <li>◆ Microplaca sensibilizada</li> <li>◆ Επικαλυμμένη μικροπλάκα</li> </ul>              |
|  | <ul style="list-style-type: none"> <li>◆ Piastra ad aghi rivestita</li> <li>◆ Pinplate sensibilisée</li> <li>◆ Beschichtete Pinplatte</li> <li>◆ Pinplate revestida</li> </ul>                                   | <ul style="list-style-type: none"> <li>◆ Coated pinplate</li> <li>◆ Pinplate sensibilizada</li> <li>◆ Επικαλυμμένη πλάκα Pin</li> </ul>                         |
|  | <ul style="list-style-type: none"> <li>◆ Tampone di lavaggio</li> <li>◆ Tampon de Lavage</li> <li>◆ Waschpuffer</li> <li>◆ Solução de lavagem</li> </ul>                                                         | <ul style="list-style-type: none"> <li>◆ Wash buffer</li> <li>◆ Solución de lavado</li> <li>◆ Ρυθμιστικό διάλυμα πλύσης</li> </ul>                              |
|  | <ul style="list-style-type: none"> <li>◆ Tampone substrato</li> <li>◆ Substrat</li> <li>◆ Substratpuffer</li> <li>◆ Substrato</li> </ul>                                                                         | <ul style="list-style-type: none"> <li>◆ Substrate buffer</li> <li>◆ Tampón sustrato</li> <li>◆ Ρυθμιστικό διάλυμα υποστρώματος</li> </ul>                      |
|  | <ul style="list-style-type: none"> <li>◆ Reagente bloccante</li> <li>◆ Solution d'Arrêt</li> <li>◆ Stopreagenz</li> <li>◆ Solução de paragem</li> </ul>                                                          | <ul style="list-style-type: none"> <li>◆ Stop solution</li> <li>◆ Solución de parada</li> <li>◆ Αντιδραστήριο διακοπής αντίδρασης</li> </ul>                    |
|  | <ul style="list-style-type: none"> <li>◆ Tampone campione</li> <li>◆ Tampon Echantillons</li> <li>◆ Probenpuffer</li> <li>◆ Diluente de amostra</li> </ul>                                                       | <ul style="list-style-type: none"> <li>◆ Sample buffer</li> <li>◆ Tampón Muestras</li> <li>◆ Ρυθμιστικό διάλυμα δειγμάτων</li> </ul>                            |

AESKU.INC 1083 Pinehurst Road - Grayson - GA - 30017 - U.S.A.